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Depression is a condition in which an individual feels lethargic, irritable, and guilty, has
difﬁculty and trouble, no enjoyment in life, mood swings, sometimes suicidal ideation and
thoughts, and loss of pleasure in activities. There are hundreds of millions of individuals
suffering from major depression disorder all over the world. This leads to a considerable
portion of the economy going for treatment as large amounts of money are spent on drugs
every year. Pharmaceutical drugs are not very effective and they also have side effects that
compound the problem. There are number of studies which shows that omega-3 fatty acids
are proving to be very effective against the treatment of major depression disorder and
other psychiatric disorders. However, the data regarding the efﬁcacy of omega-3 fatty acids
in depression treatment are conﬂicted. This article reviews the recent research showing the
relation between omega-3 fatty acids and depression. The roles of the omega-3 fatty acids
in the treatment of depression are being studied with increased pace in the last decade dueto heightened prevalence of depression. It is emphasized that omega-3 fatty acids have no
record of associated side effects, which deserves greater attention for further research.
© 2015 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license1. Introduction
Globally, depression is considered the most widespread
disease.1 Depression is a complex, polygenic, heterogeneous,
multifactorial brain disorder in which the mood of the person
is affected, so it is also known as mood disorder. Depres-
sion includes symptoms such as anxiety, feelings of lethargy,
irritability, or guilt, difﬁculty in concentrating, no or less enjoy-
ment in life, fatigue, loss of interest in daily activities, and
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loss of pleasure activities.2,3 Depression can occur in any indi-
vidual irrespective of age. Depression disorders are prevalent
in the general population, besides it is also found in comor-
bid with other disorders, which increases its burden.4,5 Owing
to its burden, it is a widely studied disorder with emphasis
on its treatment strategy. A number of natural and syntheticaculty of Life Science, Aligarh Muslim University, Aligarh, Uttar
i, India.
antidepressants have been used to treat depression. In the
last decade omega-3 fatty acids have gained special attention
regarding their efﬁcacy in depression treatment.
vier. This is an open access article under the CC BY-NC-ND license
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Omega-3 fatty acids are polyunsaturated, containing more
han one double bond. They are called omega-3 because
heir ﬁrst double bond is placed at the third carbon atom
hen counting from the methyl end of the fatty acid. In the
SA, it has been found that, in both children and adults,
mega-3-fatty acids are the most frequently used nonvitamin
upplement.6 Basic, translational, and clinical research efforts
re taking place to clarify whether this important nutritional
actor plays a role inmental illness andhealth. There are some
pidemiological data emphasizing that people who usually
onsume a diet with rich content of omega-3-fatty acids are
t lower risk of developing major depression, prenatal depres-
ion, and bipolar depression.7–9 Omega-3 fatty acids are scarce
n the western diet as compared with other countries. The
ontribution of omega-6-fatty acids, however, has developed
ery much with an emphasis on soy and genetically modiﬁed
rganisms in food production.10 It is noteworthy to mention
ere that factory farming of domesticated animals (includ-
ng ﬁsh) has led to changes in the animal diet composition
reating products having lower omega-3 fatty acid contents
han those produced earlier. The presence of a rich content of
mega-6 fatty acids in western diets is usually associated with
roinﬂammation.11 The most appropriate amount of omega-
fatty acid is a difﬁcult target to achieve, because of genetic
ariations and heterogeneity among individuals.. Omega-3 fatty acids and depression
mega-3 fatty acids are known to be important for nor-
al metabolism. Most mammals are unable to synthesize
Fig. 2 – Optimized three-dimensional molecular geometry of eicosapentaenoic acid.
omega-3 fatty acids on their own. However, through diet they
are able to obtain the shorter chain omega-3 fatty acids such
as -linolenic acid consisting of 18 carbon and three double
bonds and later on use them to produce eicosapentaenoic acid
(EPA; Fig. 1) which is considered to be a more important fatty
acid that consists of 20 carbons and ﬁve double bonds. From
EPA they further synthesize docosahexanoic acid (DHA; Fig. 2),
which is considered more crucial and consists of 22 carbons
and six double bonds.
Cell signaling and structure of the cell membrane are
changed by omega-3-fatty acids, which demonstrates that an
omega-3-fatty acid can act as an antidepressant. An attempt
to examine the quantity of omega-3 fatty acids in the brain to
investigate its effects on neurogenesis was made by He et al.12
They generated a transgenic mouse that converts omega-6
fatty acids into omega-3 fatty acids that help in increasing
the quantity of DHA in the brain, which is linked with higher
neurogenesis in the hippocampus, and show better tests of
learning and memory.12
Genetic polymorphism that provides a greater risk of
developing a depressive episodewhen treatedwith proinﬂam-
matory cytokines has only begun to be examined in recent
times. Inﬂammatory processes that occur during the course
of treatment with -interferon are linked with a high onset of
depression. Genotypes related with elevated levels of EPA and
DHA in response to immune activity are known. It is noted
that genetic polymorphisms through which omega-3 fatty
acid metabolism is inﬂuenced, consist of genes FADS1 and
FADS2 that code for desaturases, which are widespread and
required in omega-3 and omega-6 fatty acid metabolism.13
Some haplotypes are linked with more inﬂammation, having
lar geometry of docosahexaenoic acid.
metabolite prostaglandin E2 in the brain is reduced by lithium.134
greater risk of developing cardiovascular disease.14 Such hap-
lotypes are more likely to add inter-individual differences in
more thanone trait or features suchas variation in intelligence
and response to omega-3 fatty acid treatment. Whether these
genes are linked with onset of depression or whether they
can be used to ﬁnd an antidepressant treatment response to
omega-3 fatty acid are yet to be studied. Possible links exist
between the consumption of seafood and the rate of inci-
denceof disorders suchas bipolar I disorder, bipolar II disorder,
and bipolar spectrum disorder.9 Through analysis of seafood
consumption, DHA content from mother’s milk, and the inci-
dence rate of postpartum depression, it has been found that
consumption of seafood, which is a rich source of omega-3
fatty acids results in a lower prevalence of depression. Depres-
sion is almost 50 times more frequent in South Africa with a
prevalence of 24.5% than in Singapore (0.5%), compared with
a mean global incidence of 12.4%. Increased quantities of DHA
in mother’s milk and seafood consumption can lead to lower
prevalence of postpartum depression. It is evident that the
higher consumption of seafood by lactating mothers would
lead to higher DHA content in the mother’s milk. By con-
trast, the arachidonic acid, EPA, content in a mother’s milk or
noticeable seafood consumption are not found to be related to
occurrence of postpartum depression.7
A relationshipbetweendepressionand the ratio of omega-3
and omega-6 fatty acid concentration of erythrocyte phos-
pholipids and plasma was examined by Adams et al15 in
20 moderate to severe depressed patients. The ratio of ery-
throcyte arachidonic acid to EPA in a signiﬁcant correlation
with depression severity was observed. In addition, a signiﬁ-
cant negative correlation was observed between erythrocyte
EPA and depression. The authors, however, concluded that
these results cannot be explained simply by differences in the
dietary intakes of EPA.15
A screening of 3,884 individuals for depressive symptoms
at an age of 60 years or older was done in Rotterdam. A
comparison of 264 individuals with symptoms of depres-
sive symptoms against 461 reference individuals was made.16
It was observed that the patients who experienced severe
symptoms of depression contain a low concentration of
omega-3 fatty acids and a considerably higher concentration
of omega-6 fatty acids. Such relationships seem to have con-
siderable importance to disorders such as inﬂammation and
atherosclerosis.15,16
In a study by Maes et al17, a comparison was made of 36
patientswithmajor depression, 14withminordepression, and
24 individuals with no reports of depression.17 A signiﬁcantly
higher proportion of serum cholesteryl esters and phospho-
lipids such as arachidonic acid to EPA and increased levels of
omega-6/omega-3 proportion were found in those with major
depression, than in the those having no signs of depression
or minor depression. However, a signiﬁcantly lower level of
-linolenic acid and decreased overall levels of omega-3 in
serum cholesteryl esters and reduced EPA in both phospho-
lipid fractions and serum cholesteryl ester were found in the
same study. In the Maes et al17 study, 34 patients with major
depression and 14 normal volunteers were examined for their
omega-3 and omega-6 levels. A signiﬁcantly strong associ-
ation between reduced EPA and overall omega-3 levels and
an increased omega-6/omega-3 proportion in phospholipidsIntegr Med Res ( 2 0 1 5 ) 132–141
and cholesteryl esters was found in individuals experienc-
ing major depression. It has been suggested by a number of
researchers that major depression is the outcome of the sig-
niﬁcantly lower concentration of omega-3 fatty acids in the
body. However, a considerable degree of boosting of depressive
symptoms is also the result of higher levels of monosatu-
rated fatty acids and omega-6 fatty acids in phospholipids. In
another study, an estimation of erythrocyte membrane fatty
acids in 10 depressed patients and 14 comparison individuals
was made, in which researchers had taken into consideration
full dietary analysis, in addition to age, sex, stress level, and
smoking habits.18 It was reported that erythrocyte membrane
omega-3 quantity was considerably lower in the depressed
patients. In another study by Peet et al,19 similar results were
repeated where the researchers studied 15 patients having
depression and 15 properly matched healthy individuals as
comparison group. It was observed that omega-3 levels of ery-
throcytes in depressed patients were considerably poorer. The
relationship between polyunsaturated fatty acids in mildly
depressed individuals was examined by Mamalakis et al.20 In
this study, 247 healthy adults were examined; it was observed
that patients with mild depression had lower DHA levels
in the adipose tissue than the individuals without depres-
sion. An increased amount of EPA and DHA intake is related
to increased gray matter in those regions of the brain with
an important role in regulating depression and other mood
disorders.21 It has been shown in various controlled clinical
studies, that depression patients who receive omega-3 fatty
acids have shown a progress in lowering depression as com-
pared with those assigned a placebo.22,23
It should be noted that lower levels of membrane related
omega-3 fatty acid and enhanced levels of omega-6 fatty acids
may boost the rate of depression and alter the functioning
of neurons. Analogous proportions of omega-3 and omega-6
fatty acid, considered to be due to dietary intake, may clar-
ify the low prevalence of mood disorders in the east, where
large levels of fatty ﬁsh are consumed, against rates in the
west where elevated levels of saturated fat acts as nutritional
support.
Formation of neurotransmitters and prostaglandin is
affected by omega-3 and omega-6 fatty acid proportion, which
is very important in themaintenance and regulation of normal
functioning of the brain.24 There are other drugs that are used
in the treatment of depression; lithium carbonate, for exam-
ple, is used for the treatment of bipolar disorder. However, it
has been observed that arachidonic acid turnoverwas lowered
by 75% within brain phospholipids in rats fed lithium chlo-
ride for 6 weeks, whereas there were no changes observed in
the production of rat omega-3 fatty acids. Valproic acid when
given therapeutically on a long-term basis leads to a decline
in arachidonate production in rat brain. The downregulation
of gene expression and action of enzyme cytosolic phospholi-
pase A2, an enzyme that particularly releases arachidonic but
not omega-3 fatty acid from phospholipids, corresponded to
the decline of lithium’s arachidonate production.
The quantity of cyclooxygenase-2 and downstreamThis result indicates that lithium and anticonvulsants act by
targeting part of the arachidonic acid inﬂammatory pathway,
which may be highly expressed in mania.25
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Fig. 3 – Diagrammatic view of omega-3 fatty acid inﬂammation pathway. Possible molecular mechanism of action of
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DHA and EPA seem to reduce the synthesis of eicosanoids
rom their precursor arachidonic acid by two possible path-
ays. The ﬁrst is that they combine with arachidonic acid for
malgamation into membrane-based phospholipids, declin-
ng both cellular and plasma concentrations of arachidonic
cid. The other way may be that for cyclooxygenase enzyme
ystem EPA may compete with arachidonic acid and help
lock the process of proinﬂammatory eicosanoid synthesis
rom arachidonic acid (e.g., prostaglandins, thromboxanes
nd leukotrienes), prostaglandin E2 and thromboxanes B2.
HA and EPA also hamper release of proinﬂammatory
ytokines, such as interferon-, tumor necrosis factor (TNF)-
, interleukin (IL)-1, IL-2, and IL-6, which is determined by
icosanoid discharge and also linked with depression and its
orm of bipolar illness (Fig. 3).
EPA is also believed to decrease IL-1 and TNF- by inhibit-
ng nuclear factor-B. In addition to this, EPA inhibits the
pstream mitogen activated protein kinase (MAPK) pathway,
hich then results in the reduction in the activity of protein-
transcription factor. It is proposed that omega-3 fatty acids
ave a role in transcriptional regulation by phosphorylation
nhibition of JNK, ERK, and MAPK proteins, which downregu-
ates protein-1 expression.26 Furthermore, omega-3 fatty acids
re proposed to have a role in restraining nuclear factor-
B nuclear translocation secondary to IB phosphorylation27
Fig. 4).
CYP2C9 and CYP2C19 are two drug metabolic hepatic
nzymes. It has been shown that EPA has got a prohibitory
ffect on both. At high dosage, it may also hamper the activity
f CYP2D6 and CYP3A4, which are considered major enzymes
n drug metabolism.28
. More recent insights on omega-3 fatty
cids and depression
growing number of reports on omega-3 fatty acids and
epression from the past few years have been added to theliterature. There is evidence that omega-3 fatty acids are
closely linked to mental health.29 In addition to this there is
evidence that theymaybeuseful as a supplement for the treat-
ment of bipolar disorder related depression30 and evidence
that EPA-supplemented food is helpful in patients suffering
depression are well documented.31 By contrast, due to partici-
pant recall and diet-related systematic differences there is an
important complexity in interpreting the literature to speciﬁc
conclusions.32
For major depressive disorder, omega-3 fatty acids have
not, so far, proved signiﬁcant as a monotherapy.33,34 An
increase in the symptoms of depression is correlated with
lower intakes of dietary omega-3 ﬁsh oil as revealed by
various epidemiological research studies. Individuals experi-
encing the symptoms of depression also found to have lower
serum concentrations of essential fatty acids, which was also
revealed by several studies of EPA and DHA.35
In order to combat this problem, some foods are usually
recommended. Fish with red ﬂesh such as salmon or mack-
erel are a good source of omega-3 oils. Omega-3 is also present
in small amounts in some plant oils such as ﬂaxseed oil.
Omega-3 oils are fatty acids in which EPA and DHA are the two
most useful components. The more important is EPA, which
is usually considered to provide more health beneﬁts. The
long chains of unsaturated fatty acids from omega-3 oils are
regarded as important for health because they are believed
to decrease cholesterol levels and clear fatty deposits in the
arteries. The cardiovascular system is also beneﬁtted,36 and
it also helps in exacerbating dysfunctions in insulin receptor
signaling in the brain and cognition.37
There is also signiﬁcant evidence which support that
omega-3 oils can be used in the treatment for schizophrenia
and bipolar depression disorder. Besides treating depres-
sion omega-3 fatty oils may also be useful in treating the
38symptoms of dementia. Omega-3 oils are approved if a
depressed person’s diet appears to be deﬁcient of it. Omega-3
oil pills are used in combinationwith selective serotonin reup-
take inhibitors (SSRIs) and are considered as more standard
136 Integr Med Res ( 2 0 1 5 ) 132–141
Fig. 4 – Omega-3 fatty acid transcriptional regulation mechanism. ERK, extracellular signal-regulated kinase; JNK, c-Jun
N-terminal kinase.
treatment for depression as recommend by some physi-
cians.
One study showed that using omega-3 fatty acids from
marine sources results in lowering of inﬂammation markers
such as C reactive proteins, TNF- and IL-6 in the blood.39
Recently, Patrick et al40 proposed a model whereby insuf-
ﬁcient levels of vitamin D, omega-3 fatty acids, and various
other genetic factors that play a role during critical periods of
development, lead to dysfunction in serotonin activation and
function, which may be an important underlying mechanism
that may lead to depression and other neuropsychiatric disor-
ders. This model further suggests that optimizing the intake
of omega-3 fatty acids from marine sources and vitamin D
may help in modulating and preventing the severity of brain
functions.40
A recent review by Deacon et al41 formed variable conclu-
sions by systematic review and meta-analysis. Results from
the research done on the effects of omega-polyunsaturated
fatty acids on the depression related mood disorder have led
to variable results.41 Furthermore as the ﬁndings from various
research studies about omega-3 fatty acids and the treatment
of depression are conﬂicted. Keeping in view the conﬂicting
results from a number of studies there is a need for more
research on omega-3 fatty acids and depression treatment
through well-designed experiments.
A number of nutrients was reviewed against pediatric
42depression. The author was concerned about the lack of
high quality study examining the nutrients such as omega-3
fatty acids, S-adenosyl methionine, vitamin C, vitamin D,
zinc, iron, and B vitamins as antidepressants.42 High qualitystudies involving an in depth analysis about depression
treatment based on such nutrients is encouraged.
In a two-site placebo-controlled, randomized, double-blind
clinical trial,43 two omega preparations enriched with EPA
versus DHAwere examined asmonotherapy formajor depres-
sion disorder. The authors found neither EPA-enriched nor
DHA-enriched omega-3 to be superior to placebo for the treat-
ment of major depression disorder.43
There is evidence that intake of omega-3 fatty acid is
associated with reduction in the depression-like symptoms
most often in women.44 A recent study examined the effect
of diet enriched with omega-3 fatty acid in rats has shown
that it helps promote behavioral escape changes, which is
consistent with enhanced adaptive management of stressful
events suggesting that omega-3 fatty acids can help in pre-
venting the onset of stress-related depressive disorders.45 A
study was undertaken to address the question of how mater-
nal diet inﬂuences development and puberty. The researchers
examined the effect of DHA sufﬁcient and deﬁcient diets
on rat gestation, lactation and weaning periods; the ﬁnd-
ings suggest that increased resilience to emotional stressors
and decreased propensity to mood disorders, which are com-
mon occurrences during adolescence, can be controlled by
maintaining sufﬁcient DHA levels in the diet throughout
development.46 High concentration of omega-3 fatty acids
are also suggested to help in rebalancing the essential fatty
acid composition of military diet, which can possibly help in
reducing the psychiatric disorders such as depression, sui-
cide, and impulsive aggression among military personal.47
Research was conducted on nurses to manage their stress as
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heywere considered/reported tobemost vulnerable for devel-
ping depression; the authors evaluated the additive effect
f omega-3 fatty acid and mindfulness-based stress man-
gement. It was recommended that omega-3 fatty acids and
indfulness could be maintained for healthy mental state in
urses, for stress management program and reducing depres-
ion in nurses.48
In a randomized controlled trail, prenatal stress in African
merican women was examined in association with supple-
entation of omega-3 fatty acid DHA. It was concluded that
HA can attenuate the effects of late-pregnancy maternal
tress.49
Low EPA levels are found to be associated with heightened
rait aggression and impetuous patients of major depression
ith history of substance-use disorder comorbidity.50 In ado-
escents with SSRI-resistant major depression disorder, there
s robust DHA deﬁciency that can be improved by supplemen-
ationof ﬁshoil,which iswell tolerated andhelps in increasing
ong chain omega-3 fatty acids status and boosts SSRI antide-
ressant effects.51 In patients of hepatitis C depression is often
ound to be associatedwith interferon- therapy. In examining
he effect of omega-3 ECA and DHA, it was observed that ECA
utnotDHAsigniﬁcantly lowers the incidence of depression in
atients receiving interferon- therapy.52 Fish oil supplemen-
ation during critical prenatal and postnatal periods helps to
iminish anxiety, cognitive dysfunction and depression-like
ehaviors induced in rats by olfactory bulbectomy.53
Omega-3 fatty acids were evaluated with and without SSRI
uvoxamine and the ﬁndings suggest that the patients treated
ith a combination of omega-3 fatty acids and ﬂuvoxamine
howed a signiﬁcant difference compared with those treated
ith ﬂuvoxamine alone in improving depression symptoms.54
mong women in the USA, depressed symptoms were exam-
ned in relation to intake of omega-3 fatty acids and omega-6
atty acids. Higher intake of omega-3 fatty acids than omega-6
atty acids was found to be associated with decreased risk of
eightened symptoms of depression.55
Omega-3 fatty acids—mostly DHA—were also found at
ncreased levels in brain of fat-1 transgenic mice and is sug-
ested to have inﬂuence on depression and mood. Further
t is suggested that omega-3 fatty acids, particularly DHA
elps in the hippocampal neurogenesis and may help to treat
nd prevent depression.56 Boosting of standardized antide-
ressant levels of omega-3 fatty acids results an apparent
mprovement in symptoms of depression. Improvement of
epression symptoms by using fatty acids were found propor-
ional to using potential therapeutic agents such as lithium
nd lamotrigine.57 Omega-3 fatty acids such as EPA in compar-
son to DHA or placebo were observed to be of greater efﬁcacy
n adjunctive treatment in mild-to-moderate depression.58,59
. Ethyl-EPA depression treatment
ne study60 conducted a double-blind, placebo-controlled,
andomized clinical trial among middle-aged women who
ere having psychological distress and depressive symp-
oms and were using ethyl-EPA (E-EPA) and supplementation
gainst placebo. It was observed that psychological distress137
and depressive symptoms improved signiﬁcantly more with
E-EPA than placebo.60
Another randomized double-blind placebo-controlled
study examined the efﬁcacy of E-EPA in depression treatment
and bipolar depression patients in which the E-EPA was found
to be an effective and well-tolerated intervention in bipolar
depression.61
E-EPA is a synthetic derivative of EPA that has been widely
studied for its beneﬁts on health. E-EPA is widely used and
is believed to exhibit beneﬁcial antipsychotic and antidepres-
sive effects, so it receives special attention in the ﬁeld of
psychiatry.62
In psychiatric disease such as schizophrenia, E-EPA has
been examined in a number of trials,63–69 although the evi-
dence for recommendation of its use is still weak.22 As
omega-3 fatty acids have been investigated to act as inﬂam-
matory agents. Clinical depression has been found to have an
association with low-grade inﬂammation.19,70–73 A number of
clinical trials using E-EPA have been done to test this hypoth-
esis. Omega-3 fatty acids were observed to smoothen the rigid
cell membrane in participants.74 Studies also show that E-EPA
has antidepressive properties that have demonstrated efﬁcacy
against bipolar depression.60
5. Conﬂicts surrounding omega-3 fatty acid
and depression
Conﬂicting results have been reported in some studies, in
which depression prevalence and severity after myocardial
infarction were evaluated by the supplementation of the
omega-3 fatty acids ECA and DHA. No effects on the symp-
toms of depression were reported.75,76 Another conﬂicting
result from a study was reported in which the effects of ﬁsh
oil and omega-3 polyunsaturated fatty acid (PUFA) supple-
mentation were examined on the anhedonic response and
body weight in a chronic stress rat model. Neither ﬁsh oil nor
omega-3 polyunsaturated fatty acid-enriched egg yolk phos-
pholipid supplementation reversed disturbances caused by
chronic mild stress in rats.57
An examination of whether there is an increase in the
inﬂuence of serum base-brain derived neurotrophic factor
in diabetes mellitus patients with major depression disorder
using omega-3 E-EPA was made. No evidence in improvement
of brain derived neurotrophic factor was reported with sup-
plementation or E-EPA in depressed patients.77
Another study tested the efﬁcacy of omega-3 E-EPA added
as antidepressant medication as adjuvant, in the treatment
of depressive symptom in adults of diabetes mellitus. The
authors found no evidence for the efﬁcacy of E-EPA to
antidepressants.78 No signiﬁcant difference were observed on
any outcome measure between omega-3 E-EPA and placebo
group in double-blind, placebo-controlled trials.79
Many products such as prostaglandins that are involved in
omega-3 fatty acids synthesis are found to have a role in reg-
ulating information. This has led to an attribution of the link
between the omega-3 fatty acids and depression.80 Involve-
ment of omega-3 fatty acid in the regulation of inﬂammation
has been supported by in vivo81 and in vitro studies as well
as studies involving meta-analytic approaches.82 However,
r138
despite many studies supporting the inﬂammation regula-
tion, the exact nature and mechanism behind omega-3 and
inﬂammation system in still not known, which has led to
controversy.83 Owing to the number of studies supporting
claims of anti-inﬂammatory effects, it is commonly prevailed
as a belief and is still lacking evidence. Although the evidence
regarding the role of omega-3 fatty acids in the treatment
of depression is growing with continuous research, due to
the systemic differences in the diet and participant recall,
there arises a noteworthy difﬁculty in the interpretation of
the literature.32 A number of meta-analyses led to the con-
troversy on the effectiveness of omega-3 fatty acids, as the
authors of such papers ﬁnd heterogeneity among results
which can be possibly explained by publications bias.84,85 No
signiﬁcant beneﬁt of omega-3 fatty acids in major depression
disorder was suggested by the trials published by Bloch and
Hannestad.85 In the treatment of depression using omea-3
fatty acids, a signiﬁcant correlation was observed between
shorter trials of treatment and increased efﬁcacy of omega-
3 fatty acids, which further incriminates publication bias.85
However, the empirical efﬁcacy for considering the omega-3
fatty acids as an auspicious alternative for the treatment of
depression has still many unsettled questions that need to
be addressed,86 Considering the conﬂicting results surround-
ing the omega-3 fatty acid efﬁcacy, it is recommended that
environmental history be traced before treatment that can
help to use the speciﬁc approach, because environment can
be the foremost factor for any behavioral disorder.87 Many
studies have proven potential beneﬁt of the omega-3 fatty
acids for treatment of wide variety of disorders such as neuro-
logical, cerebrovascular, cardiovascular, cognitive, and mood
disorders, as well as metabolic disease. Considering the evi-
dence from the clinical trial data omega-3 fatty acids deserves
extensive deliberation and more comprehensive studies for
treatment of depression.
6. Conclusion
The literature on omega-3 fatty acids and depression treat-
ment consists of considerable claims about the efﬁcacy of
omega-3 fatty acids. However, there is a substantial num-
ber of studies that show no efﬁcacy of omega-3 fatty acids
against depression. This can possibly be explained by many
factors that may be responsible for the variable results, such
as variable experimental designs, differences in sample size,
biological and genetic differences among patients, environ-
mental variability, and variability in response to omega-3 fatty
acids. Depression is a multifactorial disorder and depression
due to insufﬁcient omega-3 fatty acids diets can be of one
type. Those patients who may have depression because of
insufﬁcient omega-3 fatty acids can respond well to the diet
containing high levels of omega-3 fatty acids and can show
positive signs regarding treatment of depression. However,
for patients who have depression due to factors other than
omega-3 fatty acids diet, expecting that type of depression
can be treated due to omega-3 fatty acid supplement does not
seem reasonable. This could be the possible reason why the
literature contains conﬂicting results on omega-3 fatty acid
efﬁcacy. To reach any conclusion regarding efﬁcacy of omega-3Integr Med Res ( 2 0 1 5 ) 132–141
fatty acids on depression treatment, it is necessary to catego-
rize the patients of depression based on their causes. Although
it is very difﬁcult in the present scenario to trace the exact
cause of depression, it is encouraging that vital research can
help us to categorize the patients of depression on the basis
of their cause which can possibly help us to narrow down the
use of omega-3 fatty acid on depression patients. At present,
it could be a premature decision to conclude anything about
omega-3 fatty acids and treatment of depression. However,
considering the individual variations in the onset of depres-
sion and response to certain treatment strategies would help
us to reach a clearer conclusion.
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